The HYDRASHIFT daratumumab and isatuximab in vitro (IVD) diagnostic test resulting of a collaboration between Sebia, Janssen and Sanofi to provide the clinical community with better tools to monitor patients with multiple myeloma in line with the International Myeloma Group’s (IMWG) latest recommendations.
These assays, intended to be used with HYDRAGEL IF, mitigates the daratumumab or isatuximab mediated interference seen in immunofixation results for patients treated with DARZALEX® or SARCLISA®, a fully human monoclonal antibody that binds to CD38.
The benefit of HYDRASHIFT has been highlighted in several scientific publications, such as the Journal of Applied Laboratory Medicine (JALM) by AACC by Thoren, Ola Landgren et al., which shows:
- HYDRASHIFT benefits for myeloma patients who are receiving daratumumab therapy through more accurate monitoring of their disease status.
- The HYDRASHIFT 2/4 daratumumab assay is a useful tool to clarify the source of an IgGk band on immunofixation and allow a patient’s M protein to be viewed without interference.
Test associated with this resource
Related instrument
Amplia gama de productos con resultados de alta calidad en electroforesis en gel.
Discover more resources on Multiple Myeloma
Software completo de análisis e interpretación de datos para los ensayos de Sebia en instrumentos de electroforesis.
Esta sección contiene información destinada a una amplia difusión y, por lo tanto, puede incluir detalles de productos o información que no esté disponible o no sea válida en su país. Póngase en contacto con su representante local de Sebia. Información destinada a profesionales sanitarios. Lea atentamente las instrucciones que figuran en los prospectos de los reactivos y en los manuales de los instrumentos.